NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Monday, Zacks reports.
A number of other research firms have also recently weighed in on NRXP. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Tuesday, November 3rd. Wall Street Zen lowered shares of NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Wolfe Research started coverage on shares of NRx Pharmaceuticals in a report on Thursday, October 15th. They issued an “outperform” rating for the company. UBS Group restated a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 26th. Finally, BTIG Research lifted their price target on shares of NRx Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, November 11th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, NRx Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $35.00.
Check Out Our Latest Stock Analysis on NRXP
NRx Pharmaceuticals Stock Performance
NASDAQ:NRXP opened at $2.45 on Monday. The stock has a 50-day simple moving average of $2.77 and a two-hundred day simple moving average of $2.97. NRx Pharmaceuticals has a 52-week low of $1.62 and a 52-week high of $5.05. The firm has a market capitalization of $106.94 million, a PE ratio of -7.21 and a beta of 2.11.
NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last issued its quarterly earnings results on Monday, November 16th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.16. The company had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $1.28 million. Equities analysts forecast that NRx Pharmaceuticals will post -1.14 earnings per share for the current fiscal year.
Institutional Investors Weigh In On NRx Pharmaceuticals
A number of hedge funds have recently made changes to their positions in the company. Squarepoint Ops LLC bought a new position in shares of NRx Pharmaceuticals during the 2nd quarter valued at approximately $54,000. SBI Securities Co. Ltd. increased its position in NRx Pharmaceuticals by 292.1% in the third quarter. SBI Securities Co. Ltd. now owns 20,001 shares of the company’s stock worth $58,000 after purchasing an additional 14,900 shares during the last quarter. Prime Capital Investment Advisors LLC bought a new stake in NRx Pharmaceuticals in the third quarter worth $364,000. Commonwealth Equity Services LLC increased its position in NRx Pharmaceuticals by 30.0% in the third quarter. Commonwealth Equity Services LLC now owns 590,768 shares of the company’s stock worth $1,725,000 after purchasing an additional 136,350 shares during the last quarter. Finally, Marshall Wace LLP raised its stake in NRx Pharmaceuticals by 411.4% during the third quarter. Marshall Wace LLP now owns 995,172 shares of the company’s stock valued at $2,906,000 after purchasing an additional 800,592 shares in the last quarter. 4.27% of the stock is currently owned by hedge funds and other institutional investors.
NRx Pharmaceuticals News Roundup
Here’s some of the latest news about NRXP:
- Positive Sentiment: The FDA approved NRx’s preservative-free ketamine ahead of its target date. The company says its commercial launch is underway, with a 17-person sales team, an initial order, and shipments expected to begin by January 2027. NRx estimates the U.S. market at about $400 million, growing more than 15% annually. NRx Q3 results and corporate update
- Positive Sentiment: NRx is targeting a rolling NDA submission for NRX-100 by year-end, with a Yale collaboration intended to support its accelerated-approval pathway. It also announced NRX-200, a subcutaneous ketamine candidate, and an $11.25 million DARPA contract to fund a Phase 3 NRX-101 trial. NRx outlines ketamine market and NRX-100 target
- Negative Sentiment: Operating loss widened to $8.1 million from $4.0 million year over year, largely amid higher selling and administrative costs tied to the launch. NRx reported $19.8 million in cash at quarter-end, making commercial execution and cash use important risks to monitor. NRx Q3 results and corporate update
NRx Pharmaceuticals Company Profile
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a focus on depression and conditions involving suicidal ideation. Its programs are investigational and have not been established as approved treatments. The company’s candidates include NRX-100, a preservative-free formulation of ketamine, and NRX-101, an oral combination of D-cycloserine and lurasidone. NRx has studied these therapies for severe depression and bipolar depression, including in patients with suicidal ideation.
Further Reading
- Five stocks we like better than NRx Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
